Actively responding to the national centralized procurement policy, Beijing Huakang Tianyi Biotechnology Co., Ltd. officially joined the national joint procurement camp. On September 1, 2025, the National Organization for Joint Procurement of High-Value Medical Consumables officially announced that Beijing Huakang Tianyi Biotechnology Co., Ltd. successfully passed the review and became an additional product enterprise for the continued procurement upon the expiration of the artificial joint cent
Actively Responding to the National Centralized Procurement Policy, Officially Joining the National Joint Procurement Camp
On September 1, 2025, the National Joint Procurement Office for High-Value Medical Consumables officially issued an announcement that Beijing Huakang Tianyi Biotech Co., Ltd. successfully passed the review and became a supplementary product enterprise for the follow-up procurement after the expiration of the centralized volume-based procurement agreement for artificial joints. This means that Huakang Tianyi's artificial joint products have been officially included in the national centralized procurement platform, and the company has thus joined the national joint procurement camp, opening a new chapter of benefiting more patients.
The centralized volume-based procurement of artificial joints is an important measure by the national level to advance the reform of high-value medical consumables. Since artificial joints were first included in centralized procurement in 2021, the average price of hip joints has dropped from 35,000 yuan to around 7,000 yuan, and the average price of knee joints has dropped from 32,000 yuan to around 5,000 yuan, with an average decrease of 82%, saving a cumulative total of over 10 billion yuan. The continued advancement of the centralized procurement policy has enabled more patients with end-stage bone and joint diseases to access high-quality and affordable artificial joint products, greatly alleviating the financial burden on patients.
Strictly Following Centralized Procurement Rules, Ceramic-Polyethylene Products Selected at Reasonable Prices
According to the supplementary product information released by the Joint Procurement Office, Huakang Tianyi applied to the Joint Procurement Office during the procurement cycle to accept the selected price of the same product system category of the enterprise. The application fully complies with the requirements of the procurement documents, and after passing the review, the enterprise's products are implemented as selected product systems. According to the centralized procurement rules, supplementary products have no agreed procurement volume in the procurement year in which the application is made, but can be used as selected product systems for clinical use by medical institutions.
The products selected by the company this time cover the core categories of artificial joints. Among them, the ceramic-polyethylene hip joint product obtained the selected qualification by virtue of reliable quality and reasonable price. The successful selection of this product marks that Huakang Tianyi's R&D and manufacturing capabilities in the field of joint implants have been recognized at the national level, and also reflects the company's firm determination to actively respond to the national healthcare reform policy and serve patients with high-quality products.
Reshaping of the Orthopedic Industry Landscape Under the Background of Centralized Procurement
The continued advancement of centralized procurement of artificial joints is profoundly reshaping the competitive landscape of the orthopedic implant industry. Data shows that during the first centralized procurement of artificial joints and the renewal bidding process, the market share of leading domestic enterprises continued to climb, and the localization rate increased significantly. In the joint field, the localization rate of ceramic-on-ceramic total hip joints has reached 37%, surpassing the level of about 30% before centralized procurement. At the same time, post-centralized procurement market competition has gradually upgraded from a single price competition to a contest of comprehensive strengths such as product quality, supply stability, and clinical service capabilities.
As a national and Beijing dual high-tech medical device manufacturing enterprise, Huakang Tianyi has the production qualification for Class III spinal implants and joint replacement implants. The company has a total land area of 35,600 m² and a total building area of 56,780 m². It is equipped with advanced digital production equipment such as five-axis machining centers, turn-mill compound machines, CNC lathes, longitudinal cutting machines, and laser metal 3D printers, achieving full-process digital quality control from raw materials to finished products. These advantages provide solid production capacity and quality assurance for the company to meet market challenges under the background of centralized procurement.
Continuously Expanding Market Coverage to Provide Patients with More Choices
After successfully being selected in the national centralized procurement, Huakang Tianyi's product supply and market expansion pace continues to accelerate. According to the information in the 2026 Shanghai coding change table for medical consumables of bone, cartilage, and soft tissue implants, Huakang Tianyi products maintain normal supply and circulation in key regional markets. In the Beijing-Tianjin-Hebei "3+N" alliance coverage area, the company has also completed the confirmation of distribution relationships for relevant products.
The deepening of the centralized procurement policy is driving the orthopedic consumables industry from "single-product competition" to "system solution" competition. In 2026, the National Healthcare Security Administration officially launched the "bundle procurement module" for orthopedic centralized procurement, requiring orders to be placed in units of complete surgical packages, mandatorily locking the standard configuration combinations and prices of selected products. This model forces enterprises to upgrade their products from "individual component optimization" to "bundle system design." With a complete joint product line and full-process manufacturing capabilities, Huakang Tianyi is actively adapting to this policy change, continuously enhancing product market competitiveness and clinical service levels within the centralized procurement framework.
